EUPRAXIA PHARMACEUTICALS

Company snapshot

Eupraxia Pharmaceuticals is a public, clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology i

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for EUPRAXIA PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for EUPRAXIA PHARMACEUTICALS.

1. Jun 5, 2026 Clinical update

   TETRACOSACTIDE , EP-104GI — Phase 2

2. May 23, 2026 Clinical update

   EP-104GI — Phase 2

3. May 23, 2026 Clinical update

   EP-104IAR 25 mg — Phase 2

4. May 23, 2026 Clinical update

   EP-104IAR — Phase 1

5. Jun 7, 2022 Patent grant

   Sustained release of formulations of local anesthetics

View all clinical trial activity →

• What is EUPRAXIA PHARMACEUTICALS?

  EUPRAXIA PHARMACEUTICALS is a pharma organization headquartered in Victoria, CA. It trades on NYSE under ticker EPRX. Primary therapeutic focus areas include Osteoarthritis, Knee, Eosinophilic esophagitis, Eosinophilic Esophagitis. NovaPharmaNews links 4 clinical program(s), 0 dr

• Is EUPRAXIA PHARMACEUTICALS publicly traded?

  Yes. EUPRAXIA PHARMACEUTICALS is listed with ticker EPRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does EUPRAXIA PHARMACEUTICALS develop or market?

  We link 1 drug profile(s) where EUPRAXIA PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/eupraxia-pharmaceuticals-inc#company-drugs.

• What are the latest developments for EUPRAXIA PHARMACEUTICALS?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does EUPRAXIA PHARMACEUTICALS focus on?

  EUPRAXIA PHARMACEUTICALS focuses on Osteoarthritis, Knee, Eosinophilic esophagitis, Eosinophilic Esophagitis based on our analysis of their pipeline programs and drug development activities.